Maks_Lab A group of former Discovery Inc. investors is set to receive $125M after settling a lawsuit related to allegations that the entertainment firm’s 2022 merger with AT&T’s (NYSE:T) WarnerMedia unit generated improper payouts worth more than $1B to company insiders. Subject to the final approval of Delaware Chancery JudgeContinue Reading
Love Employee Eisai (OTCPK:ESALF) has received the rights back to antibody drug conjugate farletuzumab ecteribulin (FZEC) after Bristol-Myers Squibb (NYSE:BMY) ended a strategic collaboration on the candidate. The Japanese pharma said it will accelerate development of the asset on its own. Eisai (ESAIY) has an ongoing phase 1 study inContinue Reading
Zhanna Hapanovich TRACON Pharmaceuticals (OTC:TCON) said it is discontinuing development of its oncology drug candidate envafolimab after a key clinical trial failed to meet its primary endpoint and will concentrate instead on exploring strategic alternatives for the company. TRACON said that the study, ENVASARC, failed to meet its primary endpointContinue Reading
